Search

Your search keyword '"Maylin, Sarah"' showing total 288 results
Start Over Author "Maylin, Sarah"
288 results on '"Maylin, Sarah"'

2. Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023.

Author

Chaix, Marie‐Laure, Terracol, Laura, Nere, Marie‐Laure, Stefic, Karl, Lascoux‐Combe, Caroline, Manda, Victoria, Sellier, Pierre, Maylin, Sarah, Molina, Jean‐Michel, Liegeon, Geoffroy, Delaugerre, Constance, and Salmona, Maud

Subjects
NUCLEOSIDE reverse transcriptase inhibitors, REVERSE transcriptase inhibitors, INTEGRASE inhibitors, INFECTION, DRUG resistance
Abstract

Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology. Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non‐nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir. Predictive sensitivity was evaluated for maraviroc and broadly neutralizing antibodies (bNAbs) (zinlirvimab and teropavimab). Between 2020 and 2023, 85 people with HIV (PWH) were diagnosed with primary HIV‐1 infection (PHI). Pol and env sequences were analyzed and TDR was characterized according to the French ANRS algorithm. The genotypic‐based prediction of bNAbs sensitivity was based on HIV env amino acid signatures I108, I201, F353 for teropavimab and N325, N332, H330 for zinlirvimab. TDR to NRTIs, NNRTIs, PIs and INIs was evidenced in 8.2%, 12.9%, 4.7%, and 5.9% strains, respectively. Ten viruses were CXCR4/dual mix. All viruses were susceptible to lenacapavir (100%) and 52% harbored resistance to fostemsavir. The genotypic profile was associated with a predictive positive value (PPV) > 83% of susceptibility to both teropavimab and zinlirvimab for 23 viruses (31%), while 22 (29%) had a PPV between 62% and 75%, suggesting reduced susceptibility to both bNAbs as soon as primary infection. The surveillance of TDR evidenced at the time of PHI is important with regard to new strategies for HIV patients with virological failure and global implementation of PrEP using NRTI, INI such as recently approved injectable cabotegravir, and future long‐acting drugs such as lenacapavir and bNAbs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

Author

Vauloup-Fellous, Christelle, Maylin, Sarah, Périllaud-Dubois, Claire, Brichler, Ségolène, Alloui, Chakib, Gordien, Emmanuel, Rameix-Welti, Marie-Anne, Gault, Elyanne, Moreau, Frédérique, Fourati, Slim, Challine, Dominique, Pawlotsky, Jean-Michel, Houhou-Fidouh, Nadhira, Damond, Florence, Mackiewicz, Vincent, Charpentier, Charlotte, Méritet, Jean-François, Rozenberg, Flore, Podglajen, Isabelle, Marot, Stéphane, Petit, Heloïse, Burrel, Sonia, Akhavan, Sepideh, Leruez-Ville, Marianne, Avettand-Fenoel, Véronique, Fourgeaud, Jacques, Guilleminot, Tiffany, Gardiennet, Elise, Bonacorsi, Stéphane, Carol, Agnès, Carcelain, Guislaine, Villemonteix, Juliette, Boukli, Narjis, Gozlan, Joël, Morand-Joubert, Laurence, Legoff, Jérome, Delaugerre, Constance, Chaix, Marie-Laure, Roque-Afonso, Ana-Maria, Dortet, Laurent, Naas, Thierry, Ronat, Jean-Baptiste, Lepape, Samuel, Marcelin, Anne-Geneviève, and Descamps, Diane

Published
2021
Full Text
View/download PDF

4. Anti-SARS-CoV-2 Neutralizing Responses in Various Populations: Use of a Rapid Surrogate Lateral Flow Assay and Correlations with Anti-RBD Antibody Levels.

Author

Gozlan, Joël, Baron, Audrey, Boyd, Anders, Salmona, Maud, Fofana, Djeneba, Minier, Marine, Gabassi, Audrey, Morand-Joubert, Laurence, Delaugerre, Constance, and Maylin, Sarah

Subjects
VACCINATION status, CHEMILUMINESCENCE assay, ANTIBODY formation, VACCINE effectiveness, COVID-19 testing
Abstract

Background: After the global COVID-19 crisis, understanding post-infectious immunity and vaccine efficacy remains crucial. This study aims to assess anti-SARS-CoV-2 immunity through a quantitative analysis of anti-receptor-binding domain (RBD) antibodies and rapid functional testing of the neutralizing humoral response. Methods: A retrospective analysis was conducted on samples from various cohorts, including partially vaccinated, fully vaccinated, post-COVID/no-vaccination, and post-COVID/vaccination individuals with various immune-competency statuses. The anti-RBD antibodies were measured using an automated chemiluminescence assay, while the neutralizing antibodies' (NAbs') activity was assessed through the lateral flow ichroma COVID-19 nAb test (LFT), a surrogate neutralization assay. Results: The analysis revealed various levels of anti-RBD antibodies and seroneutralization responses across cohorts, with the post-COVID/vaccination group demonstrating the most robust protection. A correlation between anti-RBD antibodies and seroneutralization was observed, albeit with varying strength depending on the subgroup analyzed. Longitudinal assessment following natural infection showed an initial surge followed by a decline in both measures. A cutoff of 3.0 log10 BAU/mL was established to predict significant seroneutralization. Conclusions: The ichroma™ COVID-19 nAb test displayed high specificity and emerged as a valuable tool for monitoring anti-SARS-CoV-2 immunity. These findings contribute to understand the antibody response dynamics and underscore the potential of rapid tests in predicting protection against SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)–Coinfected Patients With High HBV Replication

Author

French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups, Kouamé, Gérard-Menan, Boyd, Anders, Moh, Raoul, Badje, Anani, Gabillard, Delphine, Ouattara, Eric, Ntakpe, Jean-Baptiste, Emième, Arlette, Maylin, Sarah, Chekaraou, Mariama Abdou, Eholié, Serge-Paul, Zoulim, Fabien, Lacombe, Karine, Anglaret, Xavier, and Danel, Christine

Published
2018

6. Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial

Author

Duchêne, Gaëlle, Jegou, Carole, Adnet, Frédéric, Bouchaud, Olivier, Alloui, Chakib, Jauneau, Christine, Troisvallets, Didier, Vandemeulebroucke, Eric, Fossoux, Nadia, Raphaël, Maurice, Vincent-Cassy, Christophe, Quertainmont, Yann, Goujard, Cécile, Pallier, Coralie, Vega, Aglavène, Renaud, Bertrand, Salmon, Dominique, Krivine, Anne, Bastide, Théophile, Galichon, Bertrand, Plaisance, Patrick, Morgand, Marjolaine, Maylin, Sarah, Bercot, Béatrice, Campa, Pauline, Valin, Nadia, Boukli, Narjis, Morand-Joubert, Laurence, Verbrugghe, Rachel, Dautheville, Sandrine, Ray, Patrick, Lebrette, Marie-Gisèle, Amiel, Corinne, Lancien, Cécile, Doumenc, Benoit, Khuong, Marie-Aude, Gros, Isabelle, Mutuon, Pierre, d’Almeida, Kayigan, Fromentin, Hélène, Martin, Maria, Cossé, Charlotte, Burnet, Espérie, Leblanc, Judith, Hejblum, Gilles, Costagliola, Dominique, Durand-Zaleski, Isabelle, Lert, France, de Truchis, Pierre, Verbeke, Geert, Rousseau, Alexandra, Piquet, Hélène, Simon, François, Pateron, Dominique, Simon, Tabassome, and Crémieux, Anne-Claude

Published
2018
Full Text
View/download PDF

10. Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)

Author

Hermans, Lucas Etienne, Svicher, Valentina, Pas, Suzan Diepstraten, Salpini, Romina, Alvarez, Marta, Ari, Ziv Ben, Boland, Greet, Bruzzone, Bianca, Coppola, Nicola, Seguin-Devaux, Carole, Dyda, Tomasz, Garcia, Federico, Kaiser, Rolf, Köse, Sukran, Krarup, Henrik, Lazarevic, Ivana, Lunar, Maja M., Maylin, Sarah, Micheli, Valeria, Mor, Orna, Paraschiv, Simona, Paraskevis, Dimitrios, Poljak, Mario, Puchhammer-Stöckl, Elisabeth, Simon, François, Stanojevic, Maja, Stene-Johansen, Kathrine, Tihic, Nijaz, Trimoulet, Pascale, Verheyen, Jens, Vince, Adriana, Weis, Nina, Yalcinkaya, Tülay, Lepej, Snjezana Zidovec, Perno, Carlo, Boucher, Charles A. B., and Wensing, Annemarie M. J.

Published
2016

11. Detection of SARS-CoV-2 in Saliva and Nasopharyngeal Swabs According to Viral Variants

Author

Salmona, Maud, primary, Chaix, Marie-Laure, additional, Feghoul, Linda, additional, Mahjoub, Nadia, additional, Maylin, Sarah, additional, Schnepf, Nathalie, additional, Jacquier, Hervé, additional, Walle, Eve-Marie, additional, Helary, Marion, additional, Mellon, Guillaume, additional, Osinski, Nathalie, additional, Zebiche, Widad, additional, Achili, Yacine, additional, Amarsy, Rishma, additional, Mahé, Véronique, additional, Le Goff, Jérôme, additional, and Delaugerre, Constance, additional

Published
2022
Full Text
View/download PDF

12. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Author

Colagrossi, Luna, Hermans, Lucas E., Salpini, Romina, Di Carlo, Domenico, Pas, Suzan D., Alvarez, Marta, Ben-Ari, Ziv, Boland, Greet, Bruzzone, Bianca, Coppola, Nicola, Seguin-Devaux, Carole, Dyda, Tomasz, Garcia, Federico, Kaiser, Rolf, Köse, Sukran, Krarup, Henrik, Lazarevic, Ivana, Lunar, Maja M., Maylin, Sarah, Micheli, Valeria, Mor, Orna, Paraschiv, Simona, Paraskevis, Dimitros, Poljak, Mario, Puchhammer-Stöckl, Elisabeth, Simon, François, Stanojevic, Maja, Stene-Johansen, Kathrine, Tihic, Nijaz, Trimoulet, Pascale, Verheyen, Jens, Vince, Adriana, Lepej, Snjezana Zidovec, Weis, Nina, Yalcinkaya, Tülay, Boucher, Charles A. B., Wensing, Annemarie M. J., Perno, Carlo F., Svicher, Valentina, and on behalf of the HEPVIR working group of the European Society for translational antiviral research (ESAR)

Published
2018
Full Text
View/download PDF

13. Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients

Author

Cuffel, Alexis, primary, Maylin, Sarah, additional, Le Buanec, Helene, additional, Delaugerre, Constance, additional, Minier, Marine, additional, Bergerat, David, additional, Merandet, Marine, additional, Cassius, Charles, additional, Peffault de Latour, Régis, additional, Le Goff, Jérôme, additional, Socié, Gérard, additional, Caillat-Zucman, Sophie, additional, Robin, Marie, additional, and Xhaard, Aliénor, additional

Published
2022
Full Text
View/download PDF

22. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B Running title: Liver fibrosis evolution in HIV/HBV coinfection

Author

Dezanet, Lorenza, Miailhes, Patrick, Lascoux-Combe, Caroline, Chas, Julie, Maylin, Sarah, Gabassi, Audrey, Rougier, Hayette, Delaugerre, Constance, Lacombe, Karine, Boyd, Anders, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de maladies infectieuses et tropicales [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Service des maladies infectieuses et tropicales [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard] (IMEA), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Gestionnaire, HAL Sorbonne Université 5, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), and Service de Maladies infectieuses et tropicales [CHU Tenon]

Subjects
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

International audience; Background & AimsData on liver fibrosis evolution and its involvement in liver-related morbidity are scarce in individuals with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection during treatment. We identified profiles of liver fibrosis evolution in coinfected patients undergoing tenofovir (TDF).MethodsWe included 169 HIV-HBV-coinfected patients on TDF-based antiretroviral therapy. Virological and clinical data were obtained at TDF-initiation and every 6-12 months. From data on non-invasive liver fibrosis assessments collected yearly (FibroTest®), we established clusters of individuals with similar liver fibrosis evolution using group-based trajectory models.ResultsFour profiles of liver fibrosis evolution were established from a median follow-up of 7.6 years (IQR = 3.1-13.1): low fibrosis with no progression (29.6%, profile A), low fibrosis with progression (22.5%, profile B), moderate fibrosis with high fluctuation (39.6%, profile C), and cirrhosis with no regression (8.3%, profile D). When compared to profile A, baseline HBeAg-positive status was associated with profiles B (P = .007) and C (P = .004), older age with profiles C (P < .001) and D (P = .001), exposure to second-generation protease inhibitors with profile C (P = .004), and CD4+

Published
2021
Full Text
View/download PDF

25. Untreated highly viraemic pregnant women from Asia or sub-Saharan Africa often transmit hepatitis B virus despite serovaccination to newborns*

Author

Sellier, Pierre, Maylin, Sarah, Amarsy, Rishma, Mazeron, Marie-Christine, Larrouy, Lucile, Haïm-Boukobza, Stéphanie, Lopes, Amanda, Moreno, Maria-Dolores, Ricbourg, Aude, Simoneau, Guy, Magnier, Jean-Dominique, Mercier-Delarue, Sophie, Delcey, Véronique, Evans, John, Cambau, Emmanuelle, Barranger, Emmanuel, Simon, François, and Bergmann, Jean-François

Published
2015
Full Text
View/download PDF

27. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study

Author

Dezanet, Lorenza N C, primary, Miailhes, Patrick, additional, Lascoux-Combe, Caroline, additional, Chas, Julie, additional, Maylin, Sarah, additional, Gabassi, Audrey, additional, Rougier, Hayette, additional, Delaugerre, Constance, additional, Lacombe, Karine, additional, and Boyd, Anders, additional

Published
2021
Full Text
View/download PDF

28. Persistent HBV replication and serological response during up to fifteen years of tenofovir-based antiretroviral therapy in HIV-hepatitis B coinfected patients: a multicenter prospective cohort study

Author

Dezanet, Lorenza N. C., primary, Miailhes, Patrick, additional, Lascoux-Combe, Caroline, additional, Chas, Julie, additional, Maylin, Sarah, additional, Gabassi, Audrey, additional, Rougier, Hayette, additional, Delaugerre, Constance, additional, Lacombe, Karine, additional, and Boyd, Anders, additional

Published
2021
Full Text
View/download PDF

29. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus–Hepatitis B Virus–Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort

Author

Dezanet, Lorenza N C, primary, Kassime, Raisha, additional, Miailhes, Patrick, additional, Lascoux-Combe, Caroline, additional, Chas, Julie, additional, Maylin, Sarah, additional, Gabassi, Audrey, additional, Rougier, Hayette, additional, Delaugerre, Constance, additional, Lacombe, Karine, additional, and Boyd, Anders, additional

Published
2021
Full Text
View/download PDF

30. Erratum to: Kinetics of Hepatitis B Core\textendashRelated Antigen and Anti\textendashHepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus\textendashHepatitis B Coinfection

Author

Dezanet, Lorenza N C, Maylin, Sarah, Gabassi, Audrey, Rougier, Hayette, Miailhes, Patrick, Lascoux-Combe, Caroline, Chas, Julie, Girard, Pierre-Marie, Delaugerre, Constance, Lacombe, Karine, Boyd, Anders, Gestionnaire, Hal Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine, ex- Institut Universitaire Hématologie-IUH) (IRSL), Université Paris Cité (UPCité), Génomes, biologie cellulaire et thérapeutiques (GenCellDi (U944 / UMR7212)), Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut de Médecine et d'Epidémiologie Appliquées (IMEA), Service des maladies infectieuses et tropicales [HCL-Hôpital de la Croix Rousse], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de maladies infectieuses et tropicales [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de Maladies infectieuses et tropicales [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], and CHU Saint-Antoine [AP-HP]

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Published
2021
Full Text
View/download PDF

34. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life

Author

Asselah, Tarik, primary, Loureiro, Dimitri, additional, Le Gal, Fréderic, additional, Narguet, Stéphanie, additional, Brichler, Ségolène, additional, Bouton, Valérie, additional, Abazid, Malek, additional, Boyer, Nathalie, additional, Giuly, Nathalie, additional, Gerber, Athenais, additional, Tout, Issam, additional, Maylin, Sarah, additional, Bed, Cheikh M., additional, Marcellin, Patrick, additional, Castelnau, Corinne, additional, Gordien, Emmanuel, additional, and Mansouri, Abdellah, additional

Published
2021
Full Text
View/download PDF

35. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine-Based Preexposure Prophylaxis in 2020: A Substudy of the French National Agency for Research on AIDS and Viral Hepatitis PREVENIR and Inserm SAPRIS-Sero Cohorts

Author

Delaugerre, Constance, Assoumou, Lambert, Maylin, Sarah, Minier, Marine, Gabassi, Audrey, Genin, Michèle, Beniguel, Lydie, Ghosn, Jade, Lamballerie, Xavier de, Mouhebb, Mayssam El, Costagliola, Dominique, Carrat, Fabrice, Molina, Jean Michel, and Groups, for the PREVENIR and SAPRIS-Sero Study

Subjects
SARS-CoV-2, VIRAL hepatitis
Abstract

The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G between May and October 2020 was similar in PrEP users and in a matched population-based cohort, suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Effect of viral replication and liver fibrosis on all-cause mortality in HIV/HBV coinfected patients: a retrospective analysis of a 15-year longitudinal cohort

Author

Dezanet, Lorenza N. C., primary, Kassime, Raisha, additional, Miailhes, Patrick, additional, Lascoux-Combe, Caroline, additional, Chas, Julie, additional, Maylin, Sarah, additional, Gabassi, Audrey, additional, Rougier, Hayette, additional, Delaugerre, Constance, additional, Lacombe, Karine, additional, and Boyd, Anders, additional

Published
2021
Full Text
View/download PDF

37. Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV coinfected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy Running head: HBV profiles and mortality in HIV

Author

Kouamé, Gérard Menan, Mohareb, Amir, Gabassi, Audrey, Gabillard, Delphine, Moh, Raoul, Badjé, Anani, Emiene, Arlette, Maylin, Sarah, Menam, Herve, Hyle, Emily, Delaugerre, Constance, Danel, Christine, Anglaret, Xavier, Lacombe, Karine, Eholié, Serge, Boyd, Anders, Infectious diseases in lower-income countries [Bordeaux] (IDLIC), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Harvard Medical School [Boston] (HMS), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by the Agence Nationale de Rercheches sur le SIDA et les hépatites virales (ANRS), Paris, France.GMK also received doctoral funding from the ANRS. AMM received funding from National Institutes of Health NIAID T32AI007433and NIAID R37AI058736.EPH received funding from National Institutes of Health NHLBIK01HL123349., Gestionnaire, HAL Sorbonne Université 5, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
Hepatitis B virus, Sub‐Saharan Africa, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, virus diseases, HIV, CD4+ cell count, Mortality, digestive system diseases
Abstract

International audience; It is unknown how past and active hepatitis B virus (HBV) infection affect immunorecovery and mortality in people with HIV who initiate tenofovir‐based antiretroviral therapy (ART). Using data collected between 2008 and 2015, we studied people with HIV in sub‐Saharan Africa initiating immediate ART in the Temprano randomized control trial. We classified participants into HBV groups at ART initiation: hepatitis B surface antigen (HBsAg)‐positive with HBV DNA ≥ 2,000 IU/ml; HBsAg‐positive with HBV DNA < 2,000 IU/ml; isolated HBcAb‐positive; resolved infection (HBsAb‐positive/HBcAb‐positive); and HBV non‐immune/vaccinated (HBcAb‐negative). We compared square‐root CD4‐cell count increases using mixed‐effect, non‐linear regression adjusted for age, sex, baseline CD4 cell count, and HIV RNA. We compared all‐cause mortality using Bayesian parametric survival regression. Among 879 participants, 24 (2.7%) had HBsAg with high HBV DNA, 76 (8.6%) HBsAg with low HBV DNA, 325 (37.0%) isolated anti‐HBcAb, 226 (25.7%) resolved HBV infection and 228 (25.9%) HBV non‐immune/vaccinated. We found no significant difference in CD4 cell increases between HBV‐infection groups after adjustment (p = 0.16). Participants with HBsAg and high HBV DNA had the highest incidence of all‐cause mortality (1.9/100 person‐years, 95% Credibile Interval [CrI] = 1.0–3.4). By comparison, incidence rates of mortality were reduced by 57% (95%CrI = −79%, −13%), 60% (95%CrI = −82%, −12%) and 66% (95%CrI = −84%, −23%) in those who had isolated anti‐HBcAb‐positive, resolved HBV infection and HBV non‐immune/vaccinated, respectively. In conclusion, individuals with HIV and past HBV infection or isolated anti‐HBcAb‐positive serology, much like HBV non‐immune/vaccinated, experience lower mortality than those with HBsAg and high HBV DNA. Additional HBV‐related management would not be necessary for these individuals.

Published
2020
Full Text
View/download PDF

39. Mortality in relation to hepatitis B virus (HBV) infection status among HIV‐HBV co‐infected patients in sub‐Saharan Africa after immediate initiation of antiretroviral therapy

Author

Mohareb, Amir M., primary, Kouamé, Gérard Menan, additional, Gabassi, Audrey, additional, Gabillard, Delphine, additional, Moh, Raoul, additional, Badje, Anani, additional, Emième, Arlette, additional, Maylin, Sarah, additional, Ménan, Hervé, additional, Hyle, Emily P., additional, Delaugerre, Constance, additional, Danel, Christine, additional, Anglaret, Xavier, additional, Lacombe, Karine, additional, Eholié, Serge P., additional, and Boyd, Anders, additional

Published
2021
Full Text
View/download PDF

40. Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4+ cell counts

Author

Kouamé, Gérard M, primary, Gabillard, Delphine, additional, Moh, Raoul, additional, Badje, Anani, additional, Ntakpé, Jean B, additional, Emième, Arlette, additional, Maylin, Sarah, additional, Toni, Thomas d’Aquin, additional, Ménan, Hervé, additional, Zoulim, Fabien, additional, Danel, Christine, additional, Anglaret, Xavier, additional, Eholié, Serge, additional, Lacombe, Karine, additional, and Boyd, Anders, additional

Published
2021
Full Text
View/download PDF

43. Erratum to: Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection

Author

Dezanet, Lorenza N C, primary, Maylin, Sarah, additional, Gabassi, Audrey, additional, Rougier, Hayette, additional, Miailhes, Patrick, additional, Lascoux-Combe, Caroline, additional, Chas, Julie, additional, Girard, Pierre-Marie, additional, Delaugerre, Constance, additional, Lacombe, Karine, additional, and Boyd, Anders, additional

Published
2020
Full Text
View/download PDF

44. Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir

Author

Cruchet, Romuald, primary, Dezanet, Lorenza N C, primary, Maylin, Sarah, primary, Gabassi, Audrey, primary, Rougier, Hayette, primary, Miailhes, Patrick, primary, Lascoux-Combe, Caroline, primary, Chas, Julie, primary, Girard, Pierre-Marie, primary, Delaugerre, Constance, primary, Lacombe, Karine, primary, and Boyd, Anders, primary

Published
2020
Full Text
View/download PDF

45. A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro

Author

Salpini, Romina, primary, Piermatteo, Lorenzo, additional, Battisti, Arianna, additional, Colagrossi, Luna, additional, Aragri, Marianna, additional, Yu La Rosa, Katia, additional, Bertoli, Ada, additional, Saccomandi, Patrizia, additional, Lichtner, Miriam, additional, Marignani, Massimo, additional, Maylin, Sarah, additional, Delaugerre, Constance, additional, Morisco, Filomena, additional, Coppola, Nicola, additional, Marrone, Aldo, additional, Iapadre, Nerio, additional, Cerva, Carlotta, additional, Aquaro, Stefano, additional, Angelico, Mario, additional, Sarmati, Loredana, additional, Andreoni, Massimo, additional, Verheyen, Jens, additional, Ceccherini-Silberstein, Francesca, additional, Levrero, Massimo, additional, Perno, Carlo Federico, additional, Belloni, Laura, additional, and Svicher, Valentina, additional

Published
2020
Full Text
View/download PDF

46. Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection

Author

Dezanet, Lorenza N C, primary, Maylin, Sarah, additional, Gabassi, Audrey, additional, Rougier, Hayette, additional, Miailhes, Patrick, additional, Lascoux-Combe, Caroline, additional, Chas, Julie, additional, Girard, Pierre-Marie, additional, Delaugerre, Constance, additional, Lacombe, Karine, additional, and Boyd, Anders, additional

Published
2020
Full Text
View/download PDF

47. Evaluation of 31 Commercial SARS-CoV-2 Serology Assays

Author

Vauloup Fellous, Christelle, primary, Maylin, Sarah, additional, Dubois, Claire, additional, Brichler, Segolene, additional, Alloui, Ahmed-Chakib, additional, Gordien, Nerville-Emmanuel, additional, Rameix Welti, Marie-Anne, additional, Gault, Elyanne, additional, Moreau, Frédérique, additional, Fourati, Slim, additional, Challine, Dominique, additional, Pawlotsky, Jean michel, additional, Houhou, Nadhira, additional, Damond, Florence, additional, Mackiewicz, Vincent, additional, Charpentier, Charlotte, additional, Meritet, Jean-François, additional, Rozenberg, Flore, additional, Podglajen, Isabelle, additional, Marot, Stephane sylvain, additional, Petit, Heloise, additional, Burrel, Sonia, additional, Akhavan, Sepideh, additional, Leruez-Ville, Marianne, additional, Avettand Fenoel, Véronique, additional, Fourgeaud, Jacques, additional, Guilleminot, Tiffany, additional, Gardiennet, Elise, additional, Bonacorsi, Stéphane, additional, Carol, Agnès, additional, Carcelain, Guislaine, additional, Villemonteix, Juliette, additional, Boukli-Hacene, Narjis, additional, Gozlan, Joël-Meyer, additional, Morand-Joubert, Laurence, additional, Le Goff, Jérôme, additional, Delaugerre, Constance, additional, Chaix Baudier, Marie-Laure, additional, Roque Afonso, Anne-Marie, additional, Dortet, Laurent, additional, Naas, Thierry, additional, Rona, Jean-Baptiste, additional, Le Pape, Samuel, additional, Marcelin, Anne-Geneviève, additional, and Descamps, Diane, additional

Published
2020
Full Text
View/download PDF

49. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus–Hepatitis B Virus–Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort.

Author

Dezanet, Lorenza N C, Kassime, Raisha, Miailhes, Patrick, Lascoux-Combe, Caroline, Chas, Julie, Maylin, Sarah, Gabassi, Audrey, Rougier, Hayette, Delaugerre, Constance, Lacombe, Karine, and Boyd, Anders

Subjects
HEPATITIS B, CONFIDENCE intervals, TENOFOVIR, CIRRHOSIS of the liver, RETROSPECTIVE studies, ANTIRETROVIRAL agents, HIV, LONGITUDINAL method
Abstract

Background In individuals living with human immunodeficiency virus (HIV) and hepatitis B virus (HBV), widespread tenofovir (TDF)–containing antiretroviral therapy (ART) has led to substantial decreases in HBV-DNA and HIV-RNA detection. However, the links between viral replication, liver fibrosis, and mortality remain unclear. Methods A total of 300 individuals living with HIV-HBV and undergoing ART were prospectively followed. Virological and clinical data were obtained at baseline and every 6–12 months. We quantified the associations between HBV-DNA, HIV-RNA, and liver fibrosis with risk of all-cause mortality using a joint longitudinal survival model. Viral detection, viral loads, and time-averaged cumulative viral loads of HIV and HBV were modeled as 3 separate exposures. Results During a median of 10.5 years (interquartile range, 4.0–14.6), the proportion undergoing TDF-containing ART (baseline = 18.7%, end of follow-up = 79.1%) and with undetectable HBV-DNA (baseline = 36.7%, end of follow-up = 94.8%) substantially increased. 42 participants died (incidence rate = 1.30/100 person-years, 95% confidence interval [CI] =.96–1.76). The leading causes of death were non-AIDS/non–liver-related malignancies (28.6%), followed by liver-related (16.7%), AIDS-related (16.7%), and other (16.7%). All-cause mortality was associated with HBV-DNA viral load (adjusted hazards ratio [aHR] per log10 IU/mL = 1.41, 95% CI = 1.04–1.93, P = .03) or time-averaged cumulative HBV-DNA (aHR per log10 copy-years = 1.37, 95% CI = 1.03–1.83, P = .03), but not undetectable HBV-DNA. Advanced liver fibrosis at baseline was also associated with increased mortality rates (aHR = 2.35, 95% CI = 1.16–4.76, P  = .02). No significant association between HIV-RNA replication and mortality was observed. Conclusions Concurrent and historical HBV replication and liver fibrosis are important drivers of all-cause mortality in largely TDF-treated individuals living with HIV-HBV, despite one-fifth of deaths being liver-related. HBV-DNA and liver fibrosis remain important prognostic indicators for this patient population. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Effect of hepatitis B virus (HBV) S-gene variability on markers of replication during treated HIV-HBV infection in Western Africa

Author

Boyd, Anders, Moh, Raoul, Maylin, Sarah, Chekaraou, Mariama, Mahjoub, Nadia, Gabillard, Delphine, Anglaret, Xavier, Paul Eholié, Serge, Danel, Christine, Delaugerre, Constance, Zoulim, Fabien, Lacombe, Karine, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Treichville [Abidjan, Côte d'Ivoire] (CHU de Treichville), Programme PAC-CI, ANRS France Recherche Nord & sud Sida-hiv hépatites, Université Félix Houphouët-Boigny (UFHB), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Gestionnaire, Hal Sorbonne Université, Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)

Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, hepatitis B surface antigen, immunosuppression, surface gene, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, genetic variability, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Abstract

International audience; BACKGROUND & AIMS: Replication markers exhibit substantial variation during chronic hepatitis B virus (HBV) infection, part of which can be explained by mutations on the surface (S) gene. We aimed to identify S-gene mutations possibly influencing the quantification of HBV replication markers (MUPIQH) in HBV genotype E infection, common to Western Africa.METHODS: Seventy-three antiretroviral treatment (ART)-naïve human immunodeficiency virus (HIV)-HBV co-infected patients from Côte d'Ivoire, initiating anti-HBV-containing ART, had available HBV S-gene sequences. S-gene MUPIQHs were screened at ART initiation based on lower HBV-DNA or HBsAg quantification (qHBsAg) compared to wildtype. Their association with HBV virological response and qHBsAg slope during treatment was evaluated.RESULTS: Genotype E was predominant (95.9%). At ART initiation, median HBV-DNA was 7.27 log10 copies/mL (IQR = 5.26-8.33) and qHBsAg 4.08 log10 IU/mL (IQR = 3.49-4.61). Twelve S-gene MUPIQHs were identified among 21 patients (28.8%): sS140L (n = 4), sD144A (n = 1), sS167L (n = 2), sS174N (n = 6), sP178Q (n = 2), sG185L (n = 2), sW191L (n = 2), sP203Q/R (n = 2), sS204N/I/R/K/T/G (n = 7), sN207T (n = 2), sF212C (n = 1) and sV224A/Y (n = 7). MUPIQHs at positions s185+s191+s224 and s178+s204 were within highly covarying networks of S-gene mutations. Older age (P = 0.02), elevated transaminases (P = 0.03) and anti-hepatitis B "e" antibody-positive serology (P = 0.009) were significantly associated with prevalent MUPIQHs at ART initiation. During treatment, baseline MUPIQHs were not associated with time-to-undetectable HBV-DNA (P = 0.7) and qHBsAg levels decreased at similar rates between those with vs without MUPIQHs (P = 0.5).CONCLUSION: Several novel S-gene mutations were associated with reductions in replication markers among West African co-infected patients. These mutations, however, do not affect response during antiviral treatment. Their diagnostic and clinical consequences need clarification.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results